- ISIN
- US6963891055
- CUSIP
- 696389105
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Dec 20, 2006
Highlights
- Market Cap
- $385.78M
- Enterprise Value
- $253.15M
- EPS (TTM)
- -$0.35
- EBITDA (TTM)
- -$26.58M
- Year Range
- $0.53 - $2.86
- Target Price
- $1.50
- ROA (TTM)
- -18.12%
- ROE (TTM)
- -18.96%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
PALI Performance Chart
Palisade Bio, Inc. (PALI) is down 21.7% since the beginning of the year. At $2 per share, PALI is trading 35.6% below its 52-week high of $3. Investors who bought $1,000 worth of PALI shares 5 years ago would now be looking at an investment worth $1.
Loading charts...
Returns By Period
Palisade Bio, Inc. (PALI) has returned -21.70% so far this year and 198.07% over the past 12 months. Over the last ten years, PALI has returned -69.98% per year, falling short of the S&P 500 Index benchmark, which averaged 13.88% annually.
Palisade Bio, Inc.
- 1D
- -1.60%
- 1M
- -5.64%
- YTD
- -21.70%
- 6M
- -11.54%
- 1Y
- 198.07%
- 3Y*
- -58.69%
- 5Y*
- -77.32%
- 10Y*
- -69.98%
Benchmark (S&P 500 Index)
- 1D
- -0.37%
- 1M
- -0.01%
- YTD
- 9.16%
- 6M
- 8.64%
- 1Y
- 25.22%
- 3Y*
- 19.78%
- 5Y*
- 11.99%
- 10Y*
- 13.88%
PALI Monthly Returns History
Based on dividend-adjusted daily data since Dec 20, 2006, PALI's average daily return is -0.04%, while the average monthly return is -1.93%.
Historically, 41% of months were positive and 59% were negative. The best month was Oct 2025 with a return of +140.8%, while the worst month was Jul 2017 at -73.2%. The longest winning streak lasted 5 consecutive months, and the longest losing streak was 8 months.
On a daily basis, PALI closed higher 42% of trading days. The best single day was Dec 5, 2017 with a return of +175.9%, while the worst single day was Aug 9, 2023 at -62.7%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -36.60% | 18.79% | -1.13% | 14.29% | 6.00% | -13.21% | -21.70% | ||||||
| 2025 | -17.58% | -39.04% | -17.88% | 14.00% | -4.39% | -8.34% | 49.98% | -33.75% | 27.21% | 140.78% | 1.93% | 11.37% | 42.42% |
| 2024 | 1.61% | -32.94% | -0.72% | 0.73% | -20.07% | -6.64% | -12.89% | -9.95% | 0.57% | -23.38% | -9.56% | -32.93% | -81.36% |
| 2023 | -44.23% | -25.52% | 62.96% | -54.83% | -16.98% | 28.79% | 32.94% | -69.83% | -14.64% | -4.64% | 12.61% | -5.60% | -88.65% |
| 2022 | -7.69% | -23.33% | 15.22% | -26.42% | -32.90% | -22.03% | -5.32% | -57.87% | -39.19% | -7.98% | -14.60% | 33.68% | -92.00% |
| 2021 | 67.05% | -8.84% | 26.87% | -25.39% | -49.93% | 6.82% | -28.01% | -4.10% | -5.69% | 3.40% | -14.96% | -44.21% | -75.38% |
Benchmark Metrics
Palisade Bio, Inc. has an annualized alpha of -16.22%, beta of 0.78, and R2 of 0.02 versus S&P 500 Index. Calculated based on daily prices since December 20, 2006.
- This stock participated in 200.95% of S&P 500 Index downside but only -53.20% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.02 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- -16.22%
- Beta
- 0.78
- R²
- 0.02
- Upside Capture
- -53.20%
- Downside Capture
- 200.95%
Return for Risk
Risk / Return Rank
PALI ranks 84 for risk / return — in the top 84% of stocks on our site. This means strong returns relative to risk — exactly what professional investors look for. Well-suited for investors who want to maximize return per unit of risk.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Palisade Bio, Inc. (PALI) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| PALI | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -0.43 | ||
| Sortino ratioReturn per unit of downside risk | +0.03 | ||
| Omega ratioGain probability vs. loss probability | 1.31 | 1.37 | -0.05 |
| Calmar ratioReturn relative to maximum drawdown | 3.53 | 2.78 | +0.74 |
| Martin ratioReturn relative to average drawdown | 7.30 | 12.44 | -5.14 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Palisade Bio, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Palisade Bio, Inc. was 100.00%, occurring on Sep 10, 2025. The portfolio has not yet recovered.
The current Palisade Bio, Inc. drawdown is 100.00%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
2025 bear market2025 | -100.00%Sep 2025 | 11y 5mo | — | 12y 2moApr 2014 - now |
2012 bear market2012 | -88.86%Aug 2012 | 5y 4mo | 1y 6mo | 6y 10moApr 2007 - Mar 2014 |
2007 bear market2007 | -24.62%Mar 2007 | 1mo 23d | 16d | 2mo 9dJan 2007 - Mar 2007 |
2014 correction2014 | -18.87%Mar 2014 | 6d | 13d | 19dMar 2014 - Apr 2014 |
2007 correction2007 | -16.00%Jan 2007 | 0s | 2d | 2dJan 2007 - Jan 2007 |
Drawdown Indicators
| PALI | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -100.00% | -56.78% | -43.22% |
Max Drawdown (1Y)Largest decline over 1 year | -56.53% | -9.10% | -47.43% |
Max Drawdown (3Y)Largest decline over 3 years | -98.44% | -18.90% | -79.54% |
Max Drawdown (5Y)Largest decline over 5 years | -99.98% | -25.43% | -74.55% |
Max Drawdown (10Y)Largest decline over 10 years | -100.00% | -33.92% | -66.08% |
Current DrawdownCurrent decline from peak | -100.00% | -1.80% | -98.20% |
Average DrawdownAverage peak-to-trough decline | -76.33% | -10.71% | -65.62% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 27.25% | 2.03% | +25.22% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Palisade Bio, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Palisade Bio, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for PALI in comparison with other companies in the Biotechnology industry. Currently, PALI has a P/B value of 3.0. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with PALI
Add Palisade Bio, Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with PALI